At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 6, 2026 at 18:15 ET
Biogen acquired RayThera Inc., a private immunology biotech, adding a Phase 1 small-molecule program and pipeline assets to diversify beyond its core neurology focus. The deal's financial terms were not disclosed, limiting near-term P&L impact, but it signals continued strategic investment in immunology as a growth area.
- Acquisition of privately held RayThera Inc., focused on small-molecule immunology therapies.
- Lead program entered Phase 1 development in July 2026.
- Financial terms (upfront, milestones, deal value) not disclosed.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access